Ariel Pablos-Mendez on the past, present, and future of TB research and the TB Alliance
February 8th marks the 25th anniversary of the signing of the Cape Town Declaration, which…
Funding for TB and Neglected Disease Research Must Increase to Realize Promise of New Technologies
Statement from TB Alliance on release of the G-FINDER 2024 Neglected Disease R&D Report NEW…
Historically Successful Global Access Campaign for Pretomanid and BPaL-based Regimens Continues with Major Milestones in BRICS Countries
Throughout 2024, one of TB Alliance’s foremost priorities has been ensuring that pretomanid and BPaL-based…
TB Alliance Joins Indonesia’s High-Level Meeting on TB
BALI, Indonesia (November 11, 2024)—TB Alliance is honored to join today’s High-Level Meeting hosted by…
TB Alliance Appoints Srishti Gupta and Akshay Vaishnaw as New Members to its Board of Directors
NEW YORK (December 9, 2024)—TB Alliance welcomes Srishti Gupta, MD, MPP, MPhil, and Akshay Vaishnaw,…
TB Alliance Applauds WHO Prequalification of Macleods Pretomanid Product
NEW YORK (November 6, 2024) — Macleods, a pharmaceutical company headquartered in India, has received…
TB Alliance Awarded $7.35 Million by U.S. Department of Defense for Novel Tuberculosis Interventions
New York (October 7, 2024) – TB Alliance is proud to announce a $7.35 million…
Brazil and Philippines Accelerate Availability of Shorter Drug-Resistant Tuberculosis Treatment
MANILA (September 3, 2024) – A delegation of experts from Brazil’s National TB Program visited…
New Clinical Trial Examines Use of Novel Compound Telacebec in Buruli Ulcer Patients
NEW YORK (August 21, 2024) – In July 2024, a Phase 2 proof-of-concept study was…